25 years of global medicine approvals: A quiet milestone with big impact

For a quarter century, a special system has quietly shaped how life-saving drugs reach people worldwide. Since its launch, this program has vetted over 500 medicines, making them eligible for purchase by international agencies and governments. That’s more than just a number—it represents real access for millions who couldn’t afford branded treatments. But behind this success story lies a question: Is this system keeping up with today’s health needs? The program wasn’t created to replace national drug regulators. Instead, it was meant to offer a fast track for medicines already approved by trusted agencies. That way, countries without strong regulatory systems could still get quality treatments. Over time, though, its role has grown. Some now see it as a stamp of approval that can influence local decisions even where regulators exist. That shift raises concerns about duplication and wasted resources.What makes this program stand out is its focus on public health priorities. It doesn’t just approve any drug—it targets those most needed in poorer regions, like treatments for HIV or malaria. Yet critics argue its criteria are too narrow. As new diseases emerge and medical technology races ahead, some wonder if the system is too slow to adapt. After all, a 25-year-old process might not fit today’s urgent health challenges. Not everyone agrees on how well it works. Supporters highlight cases where the program helped countries buy drugs at lower costs, saving lives and budgets. But others point out that many approved medicines still don’t reach the people who need them most. The gap between approval and actual use remains a tough challenge.